A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Inclusion Criteria: * Signed and dated written informed consent form (ICF) in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial * Patients ≥18 years of age and over the legal age of consent as required by local legislation at the time of signature of the ICF * Presence of at least one measurable lesion according to Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 * Eastern Cooperative Oncology Group (ECOG) Score: 0 to 1 * Life expectancy ≥3 months at the start of treatment in the opinion of the Investigator. * Patients with a confirmed diagnosis of advanced, unresectable, and/or metastatic solid tumours (any type) * Patients who have failed conventional treatment or for whom no therapy of proven efficacy exists or who are not eligible for established treatment options (including anti-Programmed Cell Death 1 (PD-1) or anti-Programmed Death-Ligand 1 (PD-L1) therapies, if relevant). Patients must have exhausted available treatment options known to prolong survival for their disease * All toxicities related to previous anti-cancer therapies have resolved ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 prior to trial treatment administration (except for alopecia, peripheral neuropathy and endocrinopathies considered irreversible \[like hypothyroidism\], and amenorrhea/menstrual disorders which can be any grade) Further inclusion criteria apply Exclusion Criter…